Souhaitez-vous accéder aux communiqués récents ?

Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE DMD Clinical Trial Company Plans to Report Preliminary Results from IGNITE DMD in the First Quarter of 2019 CAMBRIDGE, Mass., Nov. ...

CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on...

CAMBRIDGE, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will participate in a question and answer format presentation at the Chardan...

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Cell & Gene Meeting on the Mesa on Wednesday,...

CAMBRIDGE, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Sukumar Nagendran, M.D., has been elected to its Board of Directors. Dr. Nagendran...

- IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed - CAMBRIDGE, Mass., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results...

Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of PresidentGilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities CAMBRIDGE, Mass., June 26, 2018 (GLOBE...

- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway - Conference Call Scheduled for Today at 8:30 A.M. ET CAMBRIDGE, Mass., June 18, 2018 (GLOBE NEWSWIRE) --...

- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -         - Company Continues to Advance Gene Therapy Portfolio - CAMBRIDGE, Mass., May 18, 2018 (GLOBE NEWSWIRE)...

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its...